Aurinia Q4 net revenue $23.4M, FY loss $181M; FY22 LUPKYNIS guidance $115-135M

Aurinia Pharmaceuticals Inc.

2021-FY EPS reported -$1.40 revenue$45,605,000

Q4 2021 net revenue $23.4M (60% increase from Q3); full year net revenue $45.6M.
Net loss Q4 $33.3M ($0.25/share) vs $8.1M ($0.06) in Q4 2020; full year $181M ($1.40/share).
FY 2022 LUPKYNIS net revenue guidance $115-135M, representing 150-200% YoY growth.
Cash, equivalents & investments $466.1M at Dec 31, 2021; raised $196.7M net via ATM at avg $19.91.
AURORA 2 continuation study shows sustained efficacy; EMA MAA on track for CHMP opinion H2 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.